Celebrex (celecoxib) is now approved in the U.S. for a hereditary form of colorectal cancer
February 2000
Celebrex (celecoxib) is now approved in the U.S. for a hereditary form of colorectal cancer.
It'll be used to help reduce the number of intestinal polyps in patients with familial adenomatous polyposis (FAP).
Blocking the COX-2 enzyme seems to reduce blood supply to the polyp and therefore inhibit growth.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive